RET and non-small cell lung carcinoma: In treatment-naïve patients with RET fusion–positive NSCLC who received pralsetinib (n = 116), the most common grade 3–4 TRAEs were neutropenia (18%), hypertension (10%), increased blood creatine phosphokinase (9%), and lymphopenia (9%).